BioSpace News Archive

Chemomab Therapeutics Ltd. today announced financial and operating results for the second quarter ended June 30, 2023, and provided a corporate update.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided its clinical update for the second quarter ended June 30, 2023.

Caring Cross announced its role in a newly published white paper from the Innovative Genomics Institute, titled “Making Genetic Therapies Affordable and Accessible.”

Microbion Corporation today announced that the company will be presenting a poster that highlights key clinical study design elements from an ongoing phase 2 study assessing safety and efficacy of topical pravibismane in subjects suffering from moderate infections associated with chronic diabetic foot ulcers at the 2023 Military Health System Research Symposium being held from August 14th to 17th, 2023, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended June 30, 2023.

Halberd Corporation’s Traumatic Brain Injury mitigation research on Halberd’s patent-pending nasal spray continues at Mississippi State University.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended June 30, 2023, and provided a business update.

Curiox Biosystems Inc., a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis, announced today the pricing of its initial public offering of 1,400,000 shares of its common stock at a price to the public of 13,000 won per share.

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company’s 2024 fiscal year.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium, in Kissimmee, Florida from the 14th to the 17th of August 2023.